Tau PET Imaging for Opioid Use Disorder
Trial Summary
If you are in the OUD groups, you must be on a stable dose of your medication-assisted treatment for at least 30 days before the screening visit. The protocol does not specify if you need to stop other medications, so it's best to discuss this with the study team.
The research highlights the importance of PET imaging in understanding opioid receptors, which are crucial in substance dependence. Although not directly related to 18F-PI-2620, the studies show that PET imaging can provide valuable insights into brain changes in opioid use disorder, suggesting potential benefits in using similar imaging techniques for treatment evaluation.
12345This treatment is unique because it uses tau PET imaging to study brain changes in opioid use disorder, focusing on the opioid receptor system, which is crucial in addiction. Unlike standard treatments that primarily target symptoms, this approach aims to understand the underlying brain mechanisms, potentially leading to more targeted therapies.
15678Eligibility Criteria
Adults aged 18-60 with opioid use disorder (OUD) are eligible for this trial. It includes those who have had an overdose treated with naloxone in the past year, those without such a history, and healthy controls without OUD or recent opioid use. Participants must be on stable medication for OUD for at least 30 days and provide informed consent.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Testing
Participants undergo PET/CT imaging to evaluate tau uptake and a comprehensive neurocognitive battery
Follow-up
Participants are monitored for safety and effectiveness after imaging and testing